News

August 3, 2020August 3, 2020

FDA Approves Tecentriq Combo for Certain Advanced Melanomas

News

The U.S. Food and Drug Administration (FDA) has approved the immunotherapy Tecentriq (atezolizumab), in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib), for the treatment of BRAF V600 mutation-positive advanced melanoma. ... Read more

July 31, 2020July 31, 2020

Yale Researcher Wins NIH Merit Award, Supporting Immunotherapy Work

News

The National Institutes of Health (NIH) has given an R37 Merit Award to support the work of Kurt Schalper, MD, PhD, in the field of immunotherapy for the next ... Read more

July 28, 2020July 28, 2020

CAR T-cell Therapy Tecartus Granted FDA Approval for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Kite Pharma’s CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for adults with relapsed or refractory mantle cell lymphoma (MCL). The ... Read more

July 27, 2020July 27, 2020

Phase 3 Trial Launched to Test Cabometyx-Tecentriq in Advanced Kidney Cancer

News

Exelixis has launched a Phase 3 trial that will investigate the safety and efficacy of a combination therapy of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) in people with advanced renal cell carcinoma ... Read more

July 24, 2020July 24, 2020

New Light-activated CAR T-cells May Help Reduce Therapy Side Effects

News

Scientists have developed a new CAR T-cell immunotherapy strategy that uses light to activate the immune cells specifically in cancerous regions. The approach, which worked well in mice, may ... Read more

July 22, 2020July 22, 2020

EMA to Review Liso-cel as CAR T-cell Therapy for Advanced Lymphomas

News

The European Medicines Agency (EMA) has agreed to review a request to approve the investigational CAR T-cell therapy, lisocabtagene maraleucel (liso-cel), for people with pretreated lymphomas. The marketing authorization application, ... Read more

July 20, 2020July 20, 2020

Imfinzi Plus Chemo Aids Survival in Inoperable Pleural Mesothelioma, Phase 2 Data Show

News

Adding Imfinzi (durvalumab) to standard first-line chemotherapy prolongs survival for adults newly diagnosed with inoperable malignant pleural mesothelioma, according to data from a Phase 2 clinical trial. This study is ... Read more

July 17, 2020July 17, 2020

FDA Grants Priority Review to Keytruda for Relapsed or Refractory Classical Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted and given priority review to Merck‘s application requesting the approval of Keytruda (pembrolizumab) as a second-line treatment for adults with relapsed ... Read more

July 15, 2020July 15, 2020

Uppsala in Last Preclinical Stage for New CAR T-cell Product for Glioblastoma

News

Researchers at Uppsala University, in Sweden, in collaboration with the SciLifeLab Drug Discovery and Development Platform, have taken “a large step forward” in developing a potential CAR T-cell therapy ... Read more

July 6, 2020July 6, 2020

First-line Tislelizumab Plus Chemo Under Review in China for Advanced NSCLC

News

The Chinese Center for Drug Evaluation (CDE) of the National Medical Products Administration has accepted for review Beigene’s application seeking approval for tislelizumab, in combination with standard chemotherapy, as a first-line treatment ... Read more

Pin It on Pinterest